-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the R&D strength of China's pharmaceutical companies has continued to increase
From the perspective of the enterprise, Hengrui Pharmaceuticals is worthy of being the "first brother of innovative drugs".
In terms of drug targets and indications, there is fierce competition among the new drugs approved in the past four years
At present, the domestic market for third-generation EGFR-TKI inhibitors is also fierce.
PARP (Polyadenosine Diphosphate Ribose Polymerase) inhibitors and BTK (Bruton's tyrosine protein kinase) inhibitors are also two major types of oncology drugs that are currently being developed very hotly
BTK is a non-receptor tyrosine kinase that plays a role in the B cell antigen receptor (BCR) and macrophage Fc receptor signaling pathways
Eliminating HIV and hepatitis C virus is a long-term responsibility for our human beings.
Anesthetics usually accompany surgical operations, but anesthetics are a small “minority” for China’s pharmaceutical industry
In the fight against diseases, especially tumors, this upgrade and fight against monsters, we seem to have been at a disadvantage.
Reference materials:
Reference materials:1.
1.
2.
3.
4.
5.
6.
https://mp.
weixin.
qq.
com/s/sG8mLP-G--0D-3haWKnGEw
